At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 85 enrolled
Drug / intervention
Aripiprazoledrug
Likely dose
Aripiprazole 5 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open- Label Rollover Study for Subjects With Schizophrenia Completing ABILIFY® (Aripiprazole) Clinical Study 31-03-241
Otsuka Pharmaceutical Development & Commercialization, Inc.·interventional·Posted Oct 27, 2009·Updated Sep 27, 2013
In Brief
A Phase 3 clinical trial evaluating Aripiprazole for Schizophrenia. Completed, enrolled 85 participants across 15 sites in 6 countries.
Detailed Summary
The purpose of this study is to test the long-term safety and tolerability of oral aripiprazole in adolescent patients with schizophrenia.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSchizophrenia
CountriesArgentina, Croatia, India, Russia, Serbia, Ukraine
Collaborators--
Timeline
Phase 3CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartApr 2006
First PostedOct 2009
Primary CompletionJul 2012
TodayJul 2026
First PostedOct 27, 2009
Enrollment StartApr 1, 2006
Primary CompletionJul 1, 2012
TodayJul 2, 2026
Enrollment to primary: 6.3 yearsPosted 16.7 years ago
Interventions
Aripiprazoledrug
Flexible dose between 5 mg and 30 mg Aripiprazole tablets.